Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Kiadis Pharma

Evaluate

Thumbnail
March 17, 2021

Fresh antitrust push hits biopharma

Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.

Thumbnail
November 02, 2020

Kiadis makes nothing into €325m

Sanofi goes all in on Kiadis's natural killer cell projects, gained through an all-stock deal in 2019.

Article image
Vantage logo
October 30, 2020

After six years Bellicum admits it’s not ready for prime time

Yet another makeover raises fresh questions over Bellicum’s technology and sees its valuation haemorrhage some more.

Article image
Vantage logo
July 08, 2020

A swift big pharma endorsement for Kiadis

Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.

Article image
Vantage logo
November 22, 2019

Allogene and the need for a reliable cell source

A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.

Article image
Vantage logo
November 14, 2019

Lead discontinuation is a start, but Kiadis’s problems continue

Vantage logo
November 04, 2019

Share price movers – October 2019

Article image
Vantage logo
November 01, 2019

Upcoming events – key tests approach for Kadmon and Surface

Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.

Article image
Vantage logo
October 18, 2019

Kiadis falls, and Bellicum could be next

EU rejection of Kiadis's stem cell transplant adjunct means that two of three players in this space have been knocked back.

Article image
Vantage logo
June 28, 2019

Twilight of the stem cell transplant adjuncts?

The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.

Article image
Vantage logo
April 17, 2019

Kiadis moves to reduce reliance on its in-house lead

Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up